Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma

Respiration

Volumn 80, Issue 6, 2010, Pages 534-542

  Zietkowski, Ziemowit ^a   Skiepko, Roman ^a   Tomasiak Lozowska, Maria M ^a   Bodzenta Lukaszyk, Anna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Asthma; Endothelin 1; Exhaled breath condensate; Omalizumab

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ENDOTHELIN 1; EOSINOPHIL CATIONIC PROTEIN; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NITRIC OXIDE; OMALIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AIRWAY REMODELING; ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERABILITY; EOSINOPHIL COUNT; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOTHERAPY; MALE; OPEN STUDY; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SEVERE PERSISTENT ASTHMA;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BREATH TESTS; ENDOTHELIN-1; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 78649331032     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317137     Document Type: Article

References (36)

1. Busse W, Elias J, Sheppard D, Banks-Schlegel S: Airway remodeling and repair. Am J Respir Crit Care Med 1999; 160:1035-1042.
2. Miller CW, Krishnaswamy N, Johnston C, Krishnaswamy G: Severe asthma and the omalizumab option. Clin Mol Allergy 2008; 6:4.
3. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H: Efficacy and tolerability of anti-immunoglobulin E therapy with omali-zumab in patients with poorly controlled (moderate to severe) allergic asthma. Allergy 2004; 59: 701-708. (Pubitemid 38850344)
4. Hamelmann E: The rationale for treating al-lergic asthma with anti-IgE. Eur Respir Rev 2007; 16:61-66.
5. Yanagisava M, Kurihara S, Kurima Y: A nov-el potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
6. Mattoli S, Mezzetti M, Riva G, Allegra L, Fasoli A: Specific binding of endothelin on human bronchial smooth muscle cells in culture and secretion of endothelin-like ma-terial from bronchial epithelial cells. Am J Resp Cell Mol Biol 1990; 3:103-108.
7. Luscher TF: Endothelin. J Cardiovasc Phar-macol 1992; 18: 15-22.
8. Xu J, Zhong NS: Mechanisms of bronchial hyperresponsiveness: the interaction of en-dothelin-1 and other cytokines. Respirology 1999; 4:413-417.
9. Huang YC, Leyko B, Frieri M: Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann Allergy Asthma Immunol 2005; 95: 443-451.
10. Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/WHO Report 2006;publication 02-3569.
11. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y: Pharmacody-namics of omalizumab: implications for op-timized dosing strategies and clinical effi-cacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19: 491-498.
12. American Thoracic Society/American Lung Association recommendations for on-line measurement of exhaled nitric oxide in adults and the recommendations for on-line, offline and nasal expired nitric oxide mea-surements in children. Am J Respir Crit Care Med 1999; 160: 2104-2117.
13. American Thoracic Society: Lung function testing: selection of reference values and in-terpretative strategies. Am Rev Respir Dis 1991; 144:1202-1218.
14. Horvath I, Hunt J, Barnes PJ: Exhaled breath condensate: methodological recommenda-tions and unresolved questions. Eur Respir J 2005; 26: 523-548.
15. Rahman I, Biswas S: Non-invasive biomark-ers of oxidative stress: reproducibility and methodological issues. Redox Rep 2004; 9: 125-143.
16. Multu GM, Garey KW, Robbins RA, Dan-ziger LH, Rubinstein I: Collection and analy-sis of exhaled breath condensate in humans. Am Respir Crit Care Med 2001; 164:731-737.
17. Hanf G, Brachmann I, Kleine-Tebbe J, Sey-bold J, Kunkel G, Suttorp N, Noga O: Oma-lizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. Allergy 2006; 61:1141-1144.
18. Platts-Mills TA: The role of immunoglobu-lin E in allergy and asthma. Am J Respir Crit Care Med 2001; 164:1-5.
19. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Tay-lor A, Matthews J, Busse WW, Holgate ST, Fahy JV: Effects of treatment with anti-im-munoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583-593.
20. Okayama Y, Ra C, Saito H: Role of mast cells in airways remodeling. Curr Opin Immunol 2007; 19: 687-693.
21. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Her-mans C, MacDonald K, Song M, Abraham I: 'Real-life' effectiveness of omalizumab in pa-tients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103: 1633-1642.
22. Holgate S, Buhl R, Bousquet J, Smith N, Pa-nahloo Z, Jimenez P: The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med 2009; 103:1098-1113.
23. Massanari M, Holgate ST, Busse WW, Ji-menez P, Kianifard F, Zeldin R: Effect of omalizumab on peripheral blood eosino-philia in allergic asthma. Respir Med 2010; 104: 188-196.
24. Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H: Exhaled nitric oxide in chil-dren with asthma receiving Xolair (omali-zumab), a monoclonal anti-immunoglobu-lin E antibody. Pediatrics 2004; 113:308-312.
25. Humbert M, Beasley R, Ayres J, Slavin R, He-bert J, Bousquet J, Beeh KM, Ramos S, Ca-nonica GW, Hedgecock S, Fox H, Blogg M, Surrey K: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled de-spite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-316.
26. Redington AE, Springall DR, Meng QH, Tuck AB, Holgate ST, Polak JM, Howarth PH: Immunoreactive endothelin in bronchi-al biopsy specimens: increased expression in asthma and modulation by corticosteroid therapy. J Allergy Clin Immunol 1997; 100: 544-552.
27. Redington AE, Springall DR, Ghatei MA, Lau LC, Bloom SR, Holgate ST, Polak JM, Howarth PH: Endothelin in bronchoalveolar lavage fluid and its relation to airflow ob-struction in asthma. Am J Respir Crit Care Med 1995; 151: 1034-1049.
28. Ehrenreich HR, Anderson CH, Fox P, Rieck-mann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS: Endothelins, pep-tides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990; 172:1741-1748.
29. Ehrenreich HR, Bur M, Rottem L, Hültner L, Hylton JB, Garfield M, Coligan JE, Metcalfe DD, Fauci AS: Endothelins belong to the as-sortment of mast cell-derived and mast cell-bound cytokines. New Biol 1991; 4:147-151.
30. Xu J, Zhong NS: The interaction of tumor ne-crosis factor-α and endothelin-1 in patho-genic models of asthma. Clin Exp Allergy 1997; 27:568-573.
31. Cunningham ME, Huribal M, Bala RJ, Mc-Millen MA: Endothelin-1 and endothelin-4 stimulate monocyte production of cyto-kines. Crit Care Med 1997; 25: 958-964.
32. Zhang S, Smartt H, Holgate ST, Roche WR: Growth factors secreted by bronchial epithe-lial cells control myofibroblasts prolifera-tion: an in vitro co-culture model of airway remodeling in asthma. Lab Invest 1999; 79: 395-405.
33. Dosanjh A, Zuraw B: Endothelin-1 (ET-1) decreases human bronchial epithelial cell migration and proliferation: implications for airway remodeling in asthma. J Asthma 2003; 40: 883-886.
34. He W-G, Xu J, Zhong NS: Effect of inhaled corticosteroids on the mRNA expressions of endothelin-1 and endothelin converting en-zyme in bronchial asthma. Chinese J Tuber-cul Respir Dis 1998; 21: 336-241.
35. Matsunaga K, Ichikawa T, Yanagisawa S, Akamatsu K, Koari A, Hirano T, Sugiura H Minakata Y, Ichinose M: Clinical application of exhaled breath condensate analysis in asthma: prediction of FEV 1 improvement by steroid therapy. Respiration 2009; 78:393-398.
36. Zietkowski Z, Skiepko R, Tomasiak MM, Bodzenta-Lukaszyk A: Endothelin-1 in ex-haled breath condensate of stable and unsta-ble asthma patients. Respir Med 2008; 102: 470-474.